- Combination bendamustine, carboplatin, and dexamethasone (BCD) delivered high, durable rates of complete remission in patients with relapsed/refractory peripheral T-cell lymphomas (R/R PTCL).
Why this matters
- High-dose chemotherapy and autologous stem cell transplant (ASCT) is an acceptable salvage strategy in eligible patients with PTCL; however, prognosis is poor in the 60%-70% of patients who are ineligible for ASCT resulting from disease progression.
- Phase 2 BENCART study of BCD in 28 patients with R/R PTCL.
- Patients in complete or partial remission (CR/PR) with 2 courses of BCD were eligible for ASCT; the remaining patients could proceed to ASCT after 4 cycles of BCD, or continue to 6 BCD cycles.
- Funding: None disclosed.
- Objective response after 2 cycles of BCD (R2):
- 54%: 19% CR; 35% PR.
- Median duration of response after R2: 5.3 (range, 0.4-21.9) months.
- Objective response after completion of planned treatment (Rmax):
- 54%: 29% CR; 25% PR.
- Median PFS:
- 4.4 (95% CI, 2.8-6.0) months overall.
- 20.2 (range, 6.3-20.5) months with BCD followed by ASCT.
- 12.4 months in patients with angioimmunoblastic T-cell lymphoma (AITL).
- Grade 3-4 toxicities (expressed as percentage of 85 cycles) included thrombocytopenia (39%) and neutropenia (18%).
- Single-group design.